admin – Page 3225 – Get News Story

Sigma Phi Epsilon Celebrates Grand Opening of New Chapter House on Greek Row at NIU

A Bold New Era Begins at 920 Hillcrest Drive for Illinois Epsilon Chapter

DeKalb, IL – April 20, 2025 – Sigma Phi Epsilon (SigEp), one of the nation’s largest and most respected fraternities, proudly announces the Grand Opening of its brand-new chapter house at 920 Hillcrest Drive, marking a monumental milestone in the revival of the Illinois Epsilon Chapter at Northern Illinois University (NIU).

The Grand Opening Celebration, held on April 12, 2025, was a truly historic day for SigEp and the broader NIU community. Distinguished guests on the program included NIU President Lisa Freeman, DeKalb Mayor Cohen Barnes, Fraternity and Sorority Life Director Vicki Gerentes, and NIU Foundation Board of Directors member Jeff Liesendahl. Their presence underscored the importance of this moment not only for the chapter but for the entire NIU campus, Greek Row, and local community.

Video Link: https://www.youtube.com/embed/6GMKxorLkJU

More than just a building, the new house represents a bold vision: “Bringing Back the Heart” of SigEp at NIU. After years of alumni-led planning, events, and tireless dedication, the chapter has returned to Greek Row—stronger, smarter, and more determined than ever to redefine leadership, brotherhood, and excellence.

“This isn’t just about opening doors,” said Bill Flack, Past Chapter President and Alumni Board member. “It’s about opening minds, reigniting our brotherhood, and creating a legacy where future generations of SigEp men can thrive. This is our house—past, present, and future—and everyone who helped build it should feel proud.”

As highlighted in a recent NIU Today feature, the Bringing Back the Heart campaign made the new facility possible—an ambitious vision and capital initiative fueled by alumni generosity, hard work, and creativity. The fundraising goal of $275,000 is gaining momentum, and every dollar is being stretched to its fullest potential thanks to the incredible support of our Trades team and alumni volunteers who donated their time, talent, and passion to the project.

Phase 1 of the renovation—featuring the fully completed Great Room, Foyer, and the first Bedroom Suite—was unveiled at the Grand Opening. Phase 2, which includes the entire first-floor bedroom suites, has begun. In the coming weeks, Phase 3 plans will be underway to renovate the remaining areas of the house. Thanks to continued fundraising support from alumni, the full renovation is on track for completion by the start of the Fall 2025 semester in August.

The newly modernized house features:

Expanded common areas to foster brotherhood, leadership, and community engagement
Enhanced safety, security, and accessibility features
The Largest Bedrooms on Greek Row
Modern and spacious Kitchen & Dining Room
2400 Square Foot Chapter / Entertainment Room
Dedicated study and collaboration spaces with high-speed connectivity and tools to support academic excellence

The Grand Opening served not only as a celebration of a new physical home but also as a recommitment to SigEp’s timeless mission: Building Balanced Men. This spirit will continue later this month as the chapter hosts the Balanced Man Scholarship Awards Banquet in the Sky Room on top of the Holmes Student Center—recognizing outstanding men of Sound Mind and Sound Body and honoring the next generation of leaders.

“This is just the beginning,” said Markus Loving ’91, project leader and alumnus. “The new house is a symbol of how a brotherhood united by vision and values can accomplish incredible things. Together, we’re setting the stage for a revitalized Greek Life at NIU—one that honors our decades of diversity, is future-focused, and built on principles that matter.”

To learn more about the Bringing Back the Heart campaign or to donate, Click Here

Media Contact
Company Name: Sigma Phi Epsilon Alumni Board
Contact Person: Markus Loving
Email: Send Email
Phone: (815) 206-8563?
Country: United States
Website: https://northernillinois.sigep.org/meet-our-chapter/sigeps-new-house/

Migraine Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Teva Pharma Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen

The Key Migraine Companies in the market include – Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.

The Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.

DelveInsight’s “Migraine Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Migraine Market Forecast

Some of the key facts of the Migraine Market Report:

The Migraine market size was valued ~USD 10.8 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In December 2024, Teva Pharmaceutical Industries has announced positive results from its multicenter Phase III SPACE trial evaluating Ajovy (fremanezumab) as a preventive treatment for episodic migraine in children and adolescents aged 6 to 17 years. This double-blind, parallel-group, randomized, placebo-controlled study showed a statistically significant decrease in migraine frequency over 12 weeks compared to placebo, with a safety profile consistent with that seen in adult patients.
In 2023, the US had the largest market size for Migraine among the 7MM, totaling approximately USD 6,790 million. This figure is projected to rise further by 2034.
In 2023, the market size for episodic migraine (comprising preventive and acute treatments) in the US was approximately USD 4,026 million, while for chronic migraine (including preventive and acute treatments), it was nearly USD 2,766 million in the same year.
In 2023, the highest patient share of Migraine in the 7MM was observed in the US, comprising 39% of the total cases, followed by Japan with approximately 14%. In European nations, the UK reported a higher number of cases, representing about 11% of the total 7MM cases.
In 2023, the estimated prevalent population of Migraine in the 7MM was approximately 119,233 cases.
The total prevalent cases of Migraine in the US are projected to see a notable Compound Annual Growth Rate (CAGR) by 2034, rising from approximately 46,140 cases in 2023.
In 2023, Germany reported the highest prevalent population of Migraine among European countries, accounting for 22%, followed by Italy. Conversely, Spain had the lowest prevalent population of Migraine, representing around 17% in the same year.
In Japan, the majority of prevalent Migraine cases in 2023 were categorized as Episodic Migraine, totaling approximately 16,331 cases. Conversely, the least prevalent cases were classified as Chronic Migraine, numbering around 950 cases in the same year.
According to analyses by DelveInsight’s experts, the majority of Migraine cases are observed in females compared to males. In 2023, there were approximately 11,535 thousand male cases and around 34,605 thousand female cases of Migraine in the US.
In the EU4 and the UK, the majority of diagnosed cases of Migraine in 2023 were categorized as Episodic Migraine, totaling approximately 15,839 thousand cases. Conversely, the least diagnosed cases were identified as Chronic Migraine, numbering around 2,411 thousand in the same year.
Key Migraine Companies: Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
Key Migraine Therapies: EMGALITY (Galcanezumab-gnlm), AJOVY (fremanezumab-vfrm), AXS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
The Migraine epidemiology based on gender analyzed that females experience a more significant impact in relation to Migraine compared to males
The Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.

Migraine Overview

Migraine is a neurological condition characterized by intense, debilitating headaches often accompanied by other symptoms. Migraines can significantly affect a person’s quality of life, with varying frequency and severity from person to person.

Get a Free sample for the Migraine Market Report

https://www.delveinsight.com/report-store/migraine-market

Migraine Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Migraine Epidemiology Segmentation:

The Migraine market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Migraine
Prevalent Cases of Migraine by severity
Gender-specific Prevalence of Migraine
Diagnosed Cases of Episodic and Chronic Migraine

Download the report to understand which factors are driving Migraine epidemiology trends @ Migraine Epidemiology Forecast

Migraine Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Migraine Therapies and Key Companies

EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company
AJOVY (fremanezumab-vfrm): Teva Pharmaceuticals
AXS-07: Axsome Therapeutics
ABP-450: AEON Biopharma, Inc.
Aimovig: Amgen
CL-H1T: Charleston Laboratories
AIMOVIG: Amgen
Fremanezumab: Teva Pharmaceuticals
Galcanezumab: Eli Lilly and Company
propranolol LA: Anne Lindblad
Atogepant: Allergan
LBR-101: Teva Branded Pharmaceutical
Atogepant: AbbVie
Galcanezumab: Eli Lilly and Company
Marcaine: Tian Medical Inc.
Atogepant: Allergan
Galcanezumab: Eli Lilly and Company
Eptinezumab: H. Lundbeck A/S
TNX-1900: Tonix Pharmaceuticals, Inc.
IONIS-PKKRx (ISIS 546254): Ionis Pharmaceuticals, Inc.

Discover more about therapies set to grab major Migraine market share @ Migraine Treatment Market

Scope of the Migraine Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Migraine Companies: Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharma, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
Key Migraine Therapies: EMGALITY (Galcanezumab-gnlm), AJOVY (fremanezumab-vfrm), XS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
Migraine Market Dynamics: Migraine market drivers and Migraine market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Migraine Unmet Needs, KOL’s views, Analyst’s views, Migraine Market Access and Reimbursement

To know more about Migraine companies working in the treatment market, visit @ Migraine Clinical Trials and Therapeutic Assessment

Table of Contents

1. Migraine Market Report Introduction

2. Executive Summary for Migraine

3. SWOT analysis of Migraine

4. Migraine Patient Share (%) Overview at a Glance

5. Migraine Market Overview at a Glance

6. Migraine Disease Background and Overview

7. Migraine Epidemiology and Patient Population

8. Country-Specific Patient Population of Migraine

9. Migraine Current Treatment and Medical Practices

10. Migraine Unmet Needs

11. Migraine Emerging Therapies

12. Migraine Market Outlook

13. Country-Wise Migraine Market Analysis (2020–2034)

14. Migraine Market Access and Reimbursement of Therapies

15. Migraine Market Drivers

16. Migraine Market Barriers

17. Migraine Appendix

18. Migraine Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Migraine Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Teva Pharma Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen

What If Growing Up Didn’t Have to Be a Mess? Actionable Life Skills for Teens & Young Adults Is the Blueprint

From financial literacy to personal safety, Maya Shine’s bestseller empowers teens to build confidence, claim their independence, and step into adulthood with the skills they need to thrive.

Maya Shine’s ground-breaking book, Actionable Life Skills for Teens & Young Adults: A Practical Guide to Self-Improvement, Education, Healthy Habits, Scoring a Good Job, Personal Finance, Cooking, Physical & Online Safety, equips the next generation with essential skills that bridge the gap between classroom learning and real-world expectations and demands. From mastering financial literacy and career readiness to securing a first apartment and staying safe in both the real and digital world, the book provides readers with the tools they need to build a confident, independent, and successful future.

The book recently became a #1 Amazon Bestseller, solidifying its place as a must-have resource for teens, young adults, and their families.

“This recognition is more than a milestone—it’s a testament to the growing need for resources that prepare teens and young adults for real-life challenges,” said Maya Shine. “I’m truly grateful for the support from parents, family members, and young readers who have found value in this book as a helpful resource for real-life preparation.”

In addition to becoming an Amazon bestseller, the book has received prestigious honors including a Book Excellence Award, a Literary Titan Gold Award, and a Readers’ Favorite Gold Award. Readers worldwide have hailed it as a “game-changer,” “the real deal,” and “a must-have for teens and parents alike.”

Notable features include a customizable 5WH2 framework that helps young readers chart their unique path to success. Shine also provides free downloadable resources to bring the book’s principles to life: the DREAM BIG Journal for self-discovery and goal setting, an Interactive Action Plan Template to turn vision into action, and a Discussion Guide to foster personal growth in group or one-on-one settings with trusted adults.

Maya Shine, a best-selling and multi-award-winning author, parent, and advocate, blends compassion, structure, and insight in this groundbreaking work. With a background in computer engineering, business, and coaching, she leverages both her lived experience and professional expertise in her mission to empower the next generation.

Parents, educators, and teens are invited to join her mission to help young people confidently spread their wings and explore new horizons. Visit mayashinebooks.com to learn more, access free resources, and be part of the growing community of NextGen Parents dedicated to raising confident, capable young adults.

The book is available in multiple formats on Amazon and at major booksellers. To be part of the movement shaping tomorrow’s leaders, purchase your copy here.

An extended Q&A interview is also available for deeper context. To request this, please contact Maya Shine through her website here.

About the Author

Maya Shine is driven like an entrepreneur, sharp like a diamond cutter, and grounded like a storyteller with something real to say. She blends science, strategy, and heart to shape the next generation — one eye on research, the other on real life, and maybe a third on the future they deserve.

Through her brand, Maya Shine, she’s building a legacy of clarity, resilience, and a bold refusal to pass on what never should have been. Her books polish complex ideas with the same care she brings to raising her child: no fluff, no nonsense — just innovative structure, critical thinking, and a touch of wit where it counts.

Her work supports parents in raising teens who lead with empathy, compassion, and responsibility — bridging generations and strengthening communities. She provides roadmaps for teens stepping into independence and for parents passing on a legacy with care. Whether it’s a life skill, a mindset shift, or a tough conversation that needs to happen, she delivers it with power and purpose, offering young readers that first breath of lift so they can spread their wings and explore new horizons.

To connect with Maya Shine, follow her on Facebook, TikTok, Instagram, and YouTube at @MayaShineBooksOfficial.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: What If Growing Up Didn’t Have to Be a Mess? Actionable Life Skills for Teens & Young Adults Is the Blueprint

DKBrænde.dk Strengthens Denmark’s Green Heating Revolution with Premium Biofuel Solutions

As Denmark continues to move toward greener energy, DKBrænde.dk is proud to be at the forefront of the transition, offering premium-quality biofuels that combine efficiency, sustainability, and convenience. The Danish-owned company, known for its reliable service and top-tier firewood, wood pellets, and briquettes, is expanding its offerings to meet rising demand and support more households in making the switch to eco-friendly heating.

“Our vision has always been clear: to provide Danish families with sustainable, affordable heating options that don’t compromise on quality,” said Jesper Guldbrandsen, Founder and CEO of DKBrænde.dk. “With the right fuel and the right service, we believe heating your home can be both climate-conscious and convenient.”

A Cleaner Burn for a Greener Future

DKBrænde.dk sources its products from certified European forests and trusted manufacturers, ensuring each log and pellet is responsibly produced and meets strict quality standards. From firewood with low moisture content for efficient combustion, to premium wood pellets (træpiller) ideal for modern stoves and boilers, every product is selected to deliver high energy output with minimal environmental impact.

Delivery Designed for the Danish Lifestyle

In response to customer feedback, DKBrænde.dk has recently enhanced its logistics network to offer more flexible and faster delivery across Denmark. Customers can now choose from:

Standard curbside delivery (1–7 business days)
Mobile forklift delivery for direct drop-off in garages, carports, or tight-access locations

This ensures firewood and pellets arrive exactly where they’re needed — saving customers time and effort, especially during the busy winter months.

Online Ordering, Real-Time Availability

DKBrænde.dk’s streamlined website makes ordering fuel simple and transparent. Customers can view real-time inventory, delivery dates, and product specifications with just a few clicks at www.dkbrænde.dk.

About DKBrænde.dk

DKBrænde.dk is a trusted supplier of biofuels across Denmark. With a commitment to sustainability, service, and quality, the company has helped thousands of Danish homes reduce their carbon footprint while enjoying reliable and affordable heat.

Media Contact
Company Name: DK Brænde
Contact Person: Jesper Guldbrandsen
Email: Send Email
Address:Hejningevej 6
City: Slagelse
Country: Denmark
Website: https://www.xn--dkbrnde-pxa.dk

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: DKBrænde.dk Strengthens Denmark’s Green Heating Revolution with Premium Biofuel Solutions

Microscopic Polyangiitis Market Growth Projections 2024-2034: DelveInsight Analysis | Novartis, Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche

The Key Microscopic Polyangiitis Companies in the market include – Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche, Novartis, and others.

DelveInsight’s “Microscopic Polyangiitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Microscopic Polyangiitis, historical and forecasted epidemiology as well as the Microscopic Polyangiitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Microscopic Polyangiitis, offering comprehensive insights into the Microscopic Polyangiitis revenue trends, prevalence, and treatment landscape. The report delves into key Microscopic Polyangiitis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Microscopic Polyangiitis therapies. Additionally, we cover the landscape of Microscopic Polyangiitis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Microscopic Polyangiitis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Microscopic Polyangiitis space.

To Know in detail about the Microscopic Polyangiitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Microscopic Polyangiitis Market Forecast

Some of the key facts of the Microscopic Polyangiitis Market Report:

The Microscopic Polyangiitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In May 2025, Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotech company dedicated to developing safe, effective, and accessible cell therapies for patients suffering from severe autoimmune diseases and cancers, has announced an investigator-initiated trial evaluating the safety, tolerability, and clinical efficacy of AlloNK combined with rituximab. This study targets patients with rheumatoid arthritis (RA), pemphigus vulgaris, granulomatosis with polyangiitis/microscopic polyangiitis, and systemic lupus erythematosus (SLE). The trial is being conducted by Integral Rheumatology & Immunology Specialists (IRIS) in an outpatient community rheumatology clinic setting.
In November 2024, A new Phase 3 clinical trial is enrolling children and adolescents with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the most common forms of ANCA-associated vasculitis (AAV), to evaluate Tavneos (avacopan) in combination with rituximab or cyclophosphamide. Amgen, the developer of Tavneos, which is approved for treating adults with severe and active GPA or MPA, provided a financial update regarding the trial. The pediatric study (NCT06321601), announced earlier this year, aims to recruit up to 20 patients, aged 6-17, at sites in Indiana, North Carolina, and Ohio. Eligible participants include those with newly diagnosed or relapsed disease, and weighing more than 15 kilograms (approximately 33 pounds).
In August 2024, Artiva Biotherapeutics, Inc. has initiated treatment for the first patient in an investigator-initiated basket trial (IIT) to evaluate AlloNK® in combination with rituximab in patients with rheumatoid arthritis, pemphigus vulgaris, granulomatosis with polyangiitis/microscopic polyangiitis, and SLE. Conducted by Integral Rheumatology & Immunology Specialists (IRIS), a community rheumatology clinic, the trial highlights the potential of making AlloNK® accessible to patients in both community settings and academic or transplant centers. The study is focused on assessing the safety, tolerability, and clinical activity of AlloNK® (also referred to as AB-101).
In 2023, the market size for microscopic polyangiitis across the 7MM was estimated to exceed USD 30 million.
Key Microscopic Polyangiitis Companies: Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche, Novartis, and others
Key Microscopic Polyangiitis Therapies: RITUXAN, TAVNEOS, Vilobelimab (IFX-1, CaCP290), Belimumab, IFX-1, Methylprednisolone, Iptacopan, and others
The Microscopic Polyangiitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Microscopic Polyangiitis pipeline products will significantly revolutionize the Microscopic Polyangiitis market dynamics.
In 2023, there were approximately 5,000 incident cases of microscopic polyangiitis across the seven major markets. This number is anticipated to decline during the forecast period, primarily due to population decreases in major contributing countries like Japan and Germany, which are expected to lead to a reduction in incidence rates.
In the US, males account for the majority of gender-specific incident cases.
Age-specific data indicates that the highest incidence of microscopic polyangiitis occurs in individuals aged 18 years and older, while those aged 0–17 years are the least affected in the US.

Microscopic Polyangiitis Overview

Microscopic Polyangiitis (MPA) is a rare autoimmune disorder that causes inflammation of small blood vessels (vasculitis), leading to damage in various organs. Commonly affected areas include the kidneys, lungs, skin, and nervous system. Symptoms may include fatigue, weight loss, fever, shortness of breath, skin rashes, and blood in urine. MPA is associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA), which help in diagnosis. If untreated, it can lead to serious complications, such as organ failure. Treatment typically involves immunosuppressive medications like corticosteroids and cyclophosphamide to control inflammation and prevent disease progression.

Get a Free sample for the Microscopic Polyangiitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market

Microscopic Polyangiitis Epidemiology

Microscopic Polyangiitis Epidemiology Segmentation:

The Microscopic Polyangiitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Microscopic Polyangiitis
Prevalent Cases of Microscopic Polyangiitis by severity
Gender-specific Prevalence of Microscopic Polyangiitis
Diagnosed Cases of Episodic and Chronic Microscopic Polyangiitis

Download the report to understand which factors are driving Microscopic Polyangiitis epidemiology trends @ Microscopic Polyangiitis Epidemiology Forecast

Microscopic Polyangiitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Microscopic Polyangiitis market or expected to get launched during the study period. The analysis covers Microscopic Polyangiitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Microscopic Polyangiitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Microscopic Polyangiitis Therapies and Key Companies

RITUXAN: Genentech
TAVNEOS: Vifor Pharma
Vilobelimab (IFX-1, CaCP290): InflaRx GmbH
Belimumab: GlaxoSmithKline
IFX-1: InflaRx GmbH
Methylprednisolone: Hoffmann-La Roche
Iptacopan: Novartis

Discover more about therapies set to grab major Microscopic Polyangiitis market share @ Microscopic Polyangiitis Treatment Landscape

Microscopic Polyangiitis Market Drivers

Advances in Diagnostic Techniques
Rising Awareness
Pipeline Therapies
Increased Healthcare Access
Growing Research Efforts

Microscopic Polyangiitis Market Barriers

Limited Awareness in Low-Income Regions
High Treatment Costs
Side Effects of Therapies
Rarity of Disease
Regulatory Challenges

Scope of the Microscopic Polyangiitis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Microscopic Polyangiitis Companies: Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche, Novartis, and others
Key Microscopic Polyangiitis Therapies: RITUXAN, TAVNEOS, Vilobelimab (IFX-1, CaCP290), Belimumab, IFX-1, Methylprednisolone, Iptacopan, and others
Microscopic Polyangiitis Therapeutic Assessment: Microscopic Polyangiitis current marketed and Microscopic Polyangiitis emerging therapies
Microscopic Polyangiitis Market Dynamics: Microscopic Polyangiitis market drivers and Microscopic Polyangiitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Microscopic Polyangiitis Unmet Needs, KOL’s views, Analyst’s views, Microscopic Polyangiitis Market Access and Reimbursement

To know more about Microscopic Polyangiitis companies working in the treatment market, visit @ Microscopic Polyangiitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Microscopic Polyangiitis Market Report Introduction

2. Executive Summary for Microscopic Polyangiitis

3. SWOT analysis of Microscopic Polyangiitis

4. Microscopic Polyangiitis Patient Share (%) Overview at a Glance

5. Microscopic Polyangiitis Market Overview at a Glance

6. Microscopic Polyangiitis Disease Background and Overview

7. Microscopic Polyangiitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Microscopic Polyangiitis

9. Microscopic Polyangiitis Current Treatment and Medical Practices

10. Microscopic Polyangiitis Unmet Needs

11. Microscopic Polyangiitis Emerging Therapies

12. Microscopic Polyangiitis Market Outlook

13. Country-Wise Microscopic Polyangiitis Market Analysis (2020–2034)

14. Microscopic Polyangiitis Market Access and Reimbursement of Therapies

15. Microscopic Polyangiitis Market Drivers

16. Microscopic Polyangiitis Market Barriers

17. Microscopic Polyangiitis Appendix

18. Microscopic Polyangiitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Microscopic Polyangiitis Market Growth Projections 2024-2034: DelveInsight Analysis | Novartis, Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche

Are Restaurant Playlists Illegal? (Spoiler Alert: If It’s Spotify, The Answer is Yes)

May 20, 2025 – That sleek Spotify Premium account you’ve been proudly connecting to your restaurant’s sound system? It’s about as legally compliant as serving homebrewed moonshine from your kitchen. Thousands of restaurant owners across the country are unknowingly turning their dining establishments into hotbeds of copyright infringement, one Ed Sheeran track at a time.

My Instore Radio

“We’ve seen the look of horror on restaurant owners’ faces when we tell them their carefully curated Spotify playlist is actually a ticking legal time bomb,” says Soren Klausen, CEO and founder of My Instore Radio. “It’s like watching someone realize they’ve been driving without insurance for years — except this speeding ticket could cost them from $750 up to $30,000… per song.”

The music licensing plot twist that’s catching restaurants off-guard? That $9.99 monthly Spotify subscription explicitly forbids commercial use in its terms and conditions — you know, that novel-length document everyone clicks “agree” to without reading.

Playing any music in a public space like a restaurant constitutes a “public performance” requiring specific licensing, and performing rights organizations are increasingly sending their version of secret shoppers to catch violations.

“One restaurant owner told us he thought paying for premium meant it was ‘premium legal,'” Klausen recounts. “Unfortunately, the law doesn’t care about your subscription tier — it cares about whether artists get paid for commercial use of their work.”

For restaurant owners currently experiencing cold sweats reading this, My Instore Radio has created the digital equivalent of a “Get Out of Jail Free” card: their “Seamless Spotify Recreation” service. This nifty solution legally recreates existing Spotify playlists with all proper licensing in place — meaning you can keep your carefully selected mood music without risking financial ruin.

“Think of us as your music amnesty program,” explains Klausen. “We take those playlists you’ve spent hours perfecting and make them legitimate, while adding professional touches like automatic explicit content filtering and scheduled transitions throughout the day.”

The service offers several upgrades from DIY approaches, including:

Daily playlist refreshes (so your regulars don’t memorize your soundtrack)
Scheduled transitions (upbeat for lunch rush, relaxed for dinner service)
Central management for chain restaurants (because nobody wants death metal in the family-friendly location)
The priceless peace of mind that comes from not wondering if that person taking notes at table 7 is a music licensing investigator

Founded in 2011 in Billund, Denmark (yes, where LEGO comes from), My Instore Radio has grown from a simple idea — “Let’s create custom radio stations for customers worldwide” — into an international music solution serving thousands of locations across more than 50 countries. Their three prestigious ‘Gazelle Awards’ recognize them as one of Denmark’s fastest-growing companies, proving that keeping businesses legally compliant can indeed be a chart-topper.

The company’s subscription-based service includes an idiot-proof “set-and-forget” media player that connects directly to existing sound systems. No computer science degree required — it’s designed so even the most technologically challenged restaurant owner can be up and running in minutes.

“We’re offering restaurant owners a free ‘Am I Accidentally Breaking Copyright Law?’ consultation,” Klausen adds. “We promise not to judge your playlist choices, even if they include excessive amounts of ‘Despacito.'”

About My Instore Radio:

My Instore Radio is a subscription-based background music streaming and digital signage solution that keeps businesses legally compliant while preventing customers from having to endure endless loops of royalty-free elevator music. From neighborhood cafés to global restaurant chains, the company makes it easy to play and manage premium curated music that won’t result in surprise legal bills. Founded in 2011, My Instore Radio has been recognized with three prestigious ‘Gazelle Awards’ as one of Denmark’s fastest-growing companies and now operates from three offices across different time zones, ensuring someone’s always available to save you from your illegal playlist habits.

For restaurant owners looking to avoid both legal pitfalls and tired music repetition, My Instore Radio now offers a free “Music Risk Assessment” along with a 14-day trial of their service. The company has also released their comprehensive guide “Finding the Perfect Background Music for Your Restaurant,” which provides tailored recommendations for every restaurant type from fine dining to fast casual.

Media Contact

Søren Klausen

My Instore Radio

Montanavej 10 7190 Billund Denmark

+1 (646) 968-0339

sales@myinstoreradio.com

Home

Media Contact
Company Name: My Instore Radio
Contact Person: Representative
Email: Send Email
Country: Denmark
Website: https://myinstoreradio.com/

Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion

The Key Metastatic Prostate Cancer Companies in the market inlcude – Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others.

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Metastatic Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Prostate Cancer Market Forecast

Some of the key facts of the Metastatic Prostate Cancer Market Report:

The Metastatic Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, The FDA has granted approval to Novartis’ radioligand therapy, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already undergone treatment with an androgen receptor pathway inhibitor (ARPI) and are suitable candidates for postponing chemotherapy.
In March 2025, MacroGenics is discontinuing the development of one of its antibody-drug conjugates (ADC) following disappointing results in a Phase II prostate cancer study. The Rockville, Maryland-based biotech announced that trials of vobramitamab duocarmazine (vobra duo) will be halted, as the safety and efficacy data from the TAMARACK Phase II study (NCT05551117) did not justify further financial investment.
In March 2025, Janux Therapeutics initiated Phase Ib expansion studies of JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial targeting advanced metastatic castration-resistant prostate cancer (mCRPC). This open-label, multicenter Phase I trial aims to evaluate the tolerability, pharmacodynamics, safety, preliminary efficacy, and pharmacokinetics of JANX007 as a standalone treatment or in combination therapy for adults with advanced mCRPC.
In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx in combination with atezolizumab for mCRPC demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.
In August 2024, Nuvation Bio announced that the US Food and Drug Administration has approved its investigational new drug application to study NUV-1511, the first clinical candidate developed from the company’s innovative drug-drug conjugate (DDC) platform.
In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
In June 2024, Kangpu Biopharmaceuticals secured FDA approval to conduct a Phase II/III trial of KPG-121 in combination with Abiraterone for metastatic castration-resistant prostate cancer (mCRPC).
In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration has granted Fast Track designation to BNT324/DB-1311 for the treatment of patients with advanced, unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed following standard systemic treatments.
In May 2024, Fusion Pharmaceuticals launched the Phase II AlphaBreak trial of FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC).
According to DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets (7MM) was approximately 8,241,400 cases in 2023. This number is expected to rise over the study period.
In 2023, the United States had the highest number of diagnosed prostate cancer cases, with approximately 1,506,200 reported cases.
In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in locally advanced stages (Stage I–III), with over 903,700 cases in 2023, followed by biochemical recurrence/progressive and metastatic cases, respectively.
Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others
Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others
The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics.

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is an advanced form of prostate cancer that has spread beyond the prostate gland to other parts of the body. This stage of prostate cancer, also known as stage IV, is characterized by the cancer’s ability to metastasize, meaning it travels through the bloodstream or lymphatic system to form new tumors in distant organs and tissues.

Get a Free sample for the Metastatic Prostate Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Metastatic Prostate Cancer Epidemiology

Metastatic Prostate Cancer Epidemiology Segmentation:

The Metastatic Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Metastatic Prostate Cancer
Prevalent Cases of Metastatic Prostate Cancer by severity
Gender-specific Prevalence of Metastatic Prostate Cancer
Diagnosed Cases of Episodic and Chronic Metastatic Prostate Cancer

Download the report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast

Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Metastatic Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Prostate Cancer Therapies and Key Companies

177Lu-PSMA-I&T: Curium US LLC
Darolutamide (Nubeqa, BAY1841788): Bayer
HB-302/HB-301: Hookipa Biotech GmbH
Enzalutamide: University Health Network
Opevesostat: Merck Sharp & Dohme
Pembrolizumab: Merck Sharp & Dohme
ARV-766 Part A&B: Arvinas Androgen Receptor
Darolutamide: UNICANCER
Apalutamide: Aragon Pharmaceuticals
REGN2810: Mark Stein
177Lu-PSMA-617: Novartis
ODM-208: Orion Corporation, Orion Pharma
Apalutamide: Janssen Research & Development
AZD0754: AstraZeneca
Enzalutamide: MedSIR
Apalutamide: Aragon Pharmaceuticals
Niraparib: Janssen Research & Development
177Lu-DOTA-rosopatamb: Telix Pharmaceuticals
Darolutamide: Alliance Foundation Trials
Tazemetostat: Epizyme, Inc.
Cabozantinib: Exelixis

Discover more about therapies set to grab major Metastatic Prostate Cancer market share @ Metastatic Prostate Cancer Treatment Landscape

Metastatic Prostate Cancer Market Strengths

The emergence of PASMA-PET imaging have significantly improved the diagnostic landscape of advance prostate cancer.
Astella’s XTANDI, which has approval in maximum prostate cancer indications is the highest revenue generator among all approved therapies in prostate cancer. Though XTANDI’s revenue is driven by prescribing volume, an increasing share of the drug’s revenue is driven by price increases in recent years.

Metastatic Prostate Cancer Market Opportunities

The developmental pipeline for mCSPC is dry compared to that of mCRPC. Thus, the market for mCSPC holds considerable scope for upcoming therapies owing to the availability of only a handful of approved drugs for its patient pool.
Although triplet therapy techniques have not yet been fully investigated, analysis shows that patients with de novo metastatic disease and a high-volume disease burden benefited most from this approach.

Scope of the Metastatic Prostate Cancer Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others
Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others
Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

To know more about Metastatic Prostate Cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Disease Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis (2020–2034)

14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17. Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion

ZHIYUN CINEPEER CX50 and CX50RGB Lights: Effortless Illumination Control in Any Scene

New product offers compact powerful lighting in the palm of your hand – ideal for video

Shenzhen, China – May 20th, 2025 – ZHIYUN is happy to announce the launch of the new CINEPEER CX50 series of compact video and photo lights, empowering content creators to create high-quality videos at an affordable price. As part of the CINEPEER lineup, the CX50 series reflects the vision of making professional-level lighting more accessible, offering ZHIYUN’s core performance in a streamlined, affordable design for everyday creators.

The CX50 series is more than 50% smaller than competing video lights with the same bright 50 watt power. Users can now carry their entire lighting setup in one lightweight bag. ZHIYUN’s custom design and high-power cooling system mean the CX50 series delivers the powerful lighting of the best video lights, and yet it can even be held in the palm of a hand. Both full RGB color and bi-color versions of this light are available for every creative scenario.

CX50RGB – atmospheric full spectrum color

The CX50RGB provides professional full-color, smooth scene lighting. With high-power RGB film-grade light mixing technology, it delivers vibrant colors with the brightness of a key light, providing concentrated beams and even light distribution. The vibrant full-color output can provide creative character lighting and create stunning, dynamic visuals on demand

CX50 – from daylight bright to soft warmth

The bi-color version of the CX50 light achieves 26,400 Lux of professional studio-level fill light with a custom high-reflection mini standard reflector, featuring a refined light angle based on optical principles carefully researched by ZHIYUN. This represents a greater than 40% increase in brightness compared to other lights with the same power, delivering true 50W full power, and meeting the color rendering needs of any standard scene – for example, supporting car shoots, theater ambiance, and more.

Versatile Assistant: Fill Light Anywhere

The ultra-compact CX50 series light is always ready to start shooting. It offers a new fill lighting experience for portraits, live streaming, social media videos, and still life shots. This light is versatile enough to handle scenes of all types and dimensions. Modifier options support Mini and Bowens mounts. The CX50 series enables professional light control while offering quick storage and easy portability. With Bluetooth networking control, the CX50 series allows network linking and light switching via ZHIYUN’s ZY Vega App on the user’s mobile phone.

A full hour of bright light from battery power

The compact design houses a 4500mAh battery, offering 32% more power than other 50W video lights. The CX50 series provides up to 60 minutes of continuous use at 100% brightness.

The CX50 series supports Power Distribution (PD) protocol USB fast charging, allowing users to charge and use the device simultaneously with a commonly-available PD-compatible fast charger or power bank. In stationary indoor setups, the AC/DC adapter and built-in cooling ensures all-day power. These multiple power supply options ensure convenience and reliability.

Recommended pricing (MSRP)

CX50 (Bi-color): $149

CX50RGB: $179

A 20% discount will be available from May 20 to June 13.

Where to buy

Available online from the ZHIYUN store: https://geni.us/ZYPR-CX50

Amazon Store: https://geni.us/AMZPR-CX50

About ZHIYUN

ZHIYUN ZHIYUN Tech is a pioneer and a world-leader in gimbals and stabilizers for everyone from professional filmmakers to amateur video creators. ZHIYUN believes in “MAKE IT REAL”: a commitment to arduous research and development to create breakthroughs in technological and industrial innovations. ZHIYUN’s standout products and features deliver everyday convenience, better experiences, and unlock new opportunities to make the imagination a reality.

Learn more about ZHIYUN Tech at www.ZHIYUN-tech.com or check them out on Facebook: @Zhiyun-Tech or follow them on Instagram: @ZHIYUN_Tech

Media Contact
Company Name: Guilin Zhishen Information Technology Co., Ltd.
Contact Person: Mei Chang
Email: Send Email
Phone: +86 400 900 6868
City: Shenzhen
Country: China
Website: https://www.zhiyun-tech.com/en

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ZHIYUN CINEPEER CX50 and CX50RGB Lights: Effortless Illumination Control in Any Scene

Veterans National Property Services, a Lake Magdalene Roofing Company, Warns Homeowners About Unlicensed Contractors

“Veterans National Property Services, a Lake Magdalene Roofing Company, Warns Homeowners About Unlicensed Contractors”

A roofing company in Lake Magdalene is issuing a community-wide reminder to verify contractor licenses before signing agreements for any roofing services

LAKE MAGDALENE, FL – A roofing company in Lake Magdalene is issuing a community-wide reminder to verify contractor licenses before signing agreements for any roofing services. Veterans National Property Services, which offers comprehensive residential roofing services and flat roofing systems in Lake Magdalene and neighboring areas such as Forest Hills, Greater Carrollwood and Greater Northdale, is responding to an increase in complaints involving unlicensed individuals performing substandard work.

Recent reports across Hillsborough County highlight that some homeowners—drawn by lower costs or urgent storm repairs—have ended up with incomplete work, unsafe structures, or legal liability. These incidents serve as a reminder of the importance of working with experienced professionals who understand Florida’s unpredictable weather, local building codes, and the demands of residential roofing.

Why Licensing Matters in Roofing Services

Licensed roofing contractors are required to meet Florida’s building codes, carry insurance, and complete projects that pass local inspections. Veterans National Property Services continues to offer trusted roofing services across Lake Magdalene, FL that include roof repairs, roof replacements, and flat roof systems—all completed to meet code and safety requirements.

Unlicensed roofing contractors may cut corners or use improper materials, putting homeowners at risk of code violations, insurance issues, or costly rework. In contrast, licensed professionals ensure that even roofing needs like hidden issues—such as poor drainage or degraded decking—are resolved with durable, code-compliant materials.

Spotting the Warning Signs of Unqualified Work

Common issues reported by Lake Magdalene, FL homeowners include missing permits, poor sealing, premature leaks, and structural shortcuts. These problems may not be immediately visible, but they can lead to major roof failures during Florida’s storm season.

Veterans National Property Services urges homeowners to schedule roof inspections before issues escalate. Inspections help identify flashing failures, blocked drainage, or age-related material wear that can become costly if ignored.

Florida Roofing Systems Require Local Expertise

Florida’s weather demands roofing systems that resist heat, moisture, and wind while complying with state and local codes. Veterans National Property Services installs roofing materials chosen for durability and performance, including asphalt shingles, pvc roofing, tile roofing, metal roofing, and PVC for low-slope structures.

Each system is selected based on the structure’s needs, with a focus on ventilation, insulation, and long-term efficiency. Licensed contractors are trained to assess all these variables—and apply them to both residential and commercial buildings.

Replacing Roofs on Older Homes Requires Extra Caution

In areas like Lake Magdalene, many homes are decades old and may have been reroofed without permits. Veterans National Property Services emphasizes the importance of a full code-compliant replacement when repairs are no longer sufficient.

Lake Magdalene homeowners working with licensed roofing contractors benefit from updated materials, thorough structural evaluations, and installations that improve energy efficiency, curb appeal, and insurance eligibility.

Flat Roofing Systems Demand Specialized Attention

Flat roofs are especially vulnerable to improper installation—often by unqualified contractors. Without the right slope, sealing methods, and material choices, pooling water and leaks are likely.

Veterans National Property Services offers licensed flat roof installation using PVC and reflective coatings to manage thermal buildup and resist water exposure. These systems are favored for low maintenance and compatibility with rooftop equipment—but only when properly installed.

Community Feedback Emphasizes Trust in Licensed Professionals

Lake Magdalene residents have shared firsthand why working with licensed professionals matters:

Michael R.: “I took a full month researching options and had seven companies come out. Veterans National stood out. From proposal to clean-up, the team made sure everything was done right.”

Jessica M.: “Our complete roof replacement was handled professionally. After a major storm, we needed fast but reliable work. Everything passed final inspection, and the cleanup was thorough. I feel the home is more secure now.”

These reviews reinforce the value of licensed, experienced teams—especially in regions with high weather risks.

Veterans National Property Services Offers Reliable Access and Support

For homeowners unsure about their current roof condition or needing urgent work after a storm, Veterans National Property Services offers free estimates and prompt roofing services. The roofing company maintains a transparent consultation process focused on compliance, communication, and results.

Whether the concern is emergency repair or long-term planning, homeowners are encouraged to confirm contractor licensing and ask about materials, permits, and inspection protocols before signing any contract.

About Veterans National Property Services

Veterans National Property Services is a trusted roofing contractor based in Lake Magdalene, FL, providing comprehensive roofing solutions for residential and commercial properties. The roofing company specializes in roof repairs, roof replacement, and flat roofing systems, using high-quality materials built for Florida’s unpredictable weather. With a team of experienced professionals, Veterans National focuses on delivering quality, ensuring customer satisfaction, and complying with the highest industry standards. Veterans National is proud to use premium roofing systems by Owens Corning and Duro Last, designed for long-term performance and protection.

Veterans National Property Services

14034 N Florida Ave. Tampa, FL 33613

(813) 609-5596

Media Contact
Company Name: Veterans National Property Services (VNPS)
Contact Person: Ruben Calles
Email: Send Email
Address:14034 N Florida Ave
City: Tampa
State: FL 33613
Country: United States
Website: https://vnpsroofing.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Veterans National Property Services, a Lake Magdalene Roofing Company, Warns Homeowners About Unlicensed Contractors

Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC

The Key Marginal Zone Lymphoma Companies in the market include – Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others.

DelveInsight’s “Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Marginal Zone Lymphoma, historical and forecasted epidemiology as well as the Marginal Zone Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Marginal Zone Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Marginal Zone Lymphoma Market Forecast

Some of the key facts of the Marginal Zone Lymphoma Market Report:

The Marginal Zone Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In February 2025, Bristol Myers Squibb (NYSE: BMY) announced that its Phase 2 TRANSCEND FL trial assessing Breyanzi® (lisocabtagene maraleucel) in adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma achieved its primary endpoint in the marginal zone lymphoma (MZL) group. The findings revealed that Breyanzi produced a statistically significant and clinically meaningful overall response rate (ORR) in this patient population.
In January 2025, Verismo Therapeutics, a clinical-stage CAR T company specializing in KIR-CAR platform technology, announced the dosing of the first patient in its CELESTIAL-301 Phase 1 clinical trial. The infusion took place at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado. The CELESTIAL-301 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of SynKIR™-310 in patients with relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL). This Phase 1 multicenter trial is enrolling patients who have previously undergone CAR T therapy but relapsed or became refractory, as well as those who have never received CAR T therapy.
In August 2024, The UK National Institute for Health and Care Excellence (NICE) has endorsed BeiGene’s Zanubrutinib (Brukinsa) for treating marginal zone lymphoma (MZL), a form of blood cancer, within the National Health Service (NHS). This approval introduces a new treatment option for patients in England, with the potential to slow cancer progression and reduce the need for additional chemotherapy.
In 2023, the United States recorded the highest number of marginal zone lymphoma (MZL) incidence cases among the 7MM, exceeding 8,000 cases. This number is projected to grow throughout the forecast period.
In gender-specific Marginal Zone Lymphoma incidence cases, males represent the predominant group.
In 2023, MALT lymphoma accounted for the largest proportion of incident cases in the US, comprising approximately 70%, followed by SMZL and NMZL.
In the US in 2023, stage-specific incidence of Marginal Zone Lymphoma was highest for Stage III-IV cases, followed by Stage I and Stage II.
YESCARTA and BREYANZI are gaining recognition as promising treatments for MZL, with BREYANZI anticipated to receive approval for third-line (3L+) MZL cases by 2026.
Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
The Marginal Zone Lymphoma epidemiology based on gender analyzed that a higher number of males were affected by this disease, i.e., ~54%of the total incident MZL population in the United States, which is equivalent to ~4,300 cases. In comparison to this, for females, the number of cases observed was ~3,700 in 2022.
The Marginal Zone Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Marginal Zone Lymphoma pipeline products will significantly revolutionize the Marginal Zone Lymphoma market dynamics.

Marginal Zone Lymphoma Overview

Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma, a cancer that originates in white blood cells called lymphocytes. MZL specifically affects a subset of these lymphocytes known as marginal zone B-cells, which are found at the edges, or margins, of lymphoid tissues like the lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT) such as the stomach, salivary glands, or other organs.

Get a Free sample for the Marginal Zone Lymphoma Market Forecast, Size & Share Analysis Report:

http://delveinsight.com/report-store/marginal-zone-lymphoma-market

Marginal Zone Lymphoma Epidemiology

Marginal Zone Lymphoma Epidemiology Segmentation:

The Marginal Zone Lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Marginal Zone Lymphoma
Prevalent Cases of Marginal Zone Lymphoma by severity
Gender-specific Prevalence of Marginal Zone Lymphoma
Diagnosed Cases of Episodic and Chronic Marginal Zone Lymphoma

Download the report to understand which factors are driving Marginal Zone Lymphoma epidemiology trends @ Marginal Zone Lymphoma Epidemiology Forecast

Marginal Zone Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Marginal Zone Lymphoma market or expected to get launched during the study period. The analysis covers Marginal Zone Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Marginal Zone Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Marginal Zone Lymphoma Therapies and Key Companies

REVLIMID (lenalidomide): Bristol-Myers Squibb
UKONIQ (umbralisib): TG Therapeutics
BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb
Yescarta: Gilead Sciences
Calquence: AstraZeneca
Betalutin: Nordic Nanovector
Obinutuzumab: Christian Buske
Rituximab: AbbVie
Ibrutinib: Pharmacyclics LLC
HMPL-689: Hutchison Medipharma
Zanubrutinib: Beigene
tafasitamab: Incyte Corporation
EO2463: Enterome

Discover more about therapies set to grab major Marginal Zone Lymphoma market share @ Marginal Zone Lymphoma Treatment Landscape

Scope of the Marginal Zone Lymphoma Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Marginal Zone Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Marginal Zone Lymphoma Market Access and Reimbursement

To know more about Marginal Zone Lymphoma companies working in the treatment market, visit @ Marginal Zone Lymphoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Marginal Zone Lymphoma Market Report Introduction

2. Executive Summary for Marginal Zone Lymphoma

3. SWOT analysis of Marginal Zone Lymphoma

4. Marginal Zone Lymphoma Patient Share (%) Overview at a Glance

5. Marginal Zone Lymphoma Market Overview at a Glance

6. Marginal Zone Lymphoma Disease Background and Overview

7. Marginal Zone Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Marginal Zone Lymphoma

9. Marginal Zone Lymphoma Current Treatment and Medical Practices

10. Marginal Zone Lymphoma Unmet Needs

11. Marginal Zone Lymphoma Emerging Therapies

12. Marginal Zone Lymphoma Market Outlook

13. Country-Wise Marginal Zone Lymphoma Market Analysis (2020–2034)

14. Marginal Zone Lymphoma Market Access and Reimbursement of Therapies

15. Marginal Zone Lymphoma Market Drivers

16. Marginal Zone Lymphoma Market Barriers

17. Marginal Zone Lymphoma Appendix

18. Marginal Zone Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC